Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study

This multicentre phase II study was aimed at investigating the activity and safety of pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) as front-line therapy in a large series of chemotherapy-naïve recurrent/metastatic breast cancer patients. From June 2003 to December 2006, a total of 71...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamo, V, Lorusso, V, Rossello, R, Adamo, B, Ferraro, G, Lorusso, D, Condemi, G, Priolo, D, Di Lullo, L, Paglia, A, Pisconti, S, Scambia, G, Ferrandina, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441953/
https://www.ncbi.nlm.nih.gov/pubmed/18493232
http://dx.doi.org/10.1038/sj.bjc.6604409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441953/
https://www.ncbi.nlm.nih.gov/pubmed/18493232
http://dx.doi.org/10.1038/sj.bjc.6604409

Ejemplares similares